NCT04174716已完成1 期
An Open-label, Multi-center, Phase 1b/2a Basket Trial of IDX-1197 in Patients With Homologous Recombination Repair Mutated Solid Tumors
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 108
- 试验地点
- 26
- 主要终点
- objective response rate (ORR)
研究概览
简要总结
This study is a Phase 1b/2a basket trial to assess safety and efficacy of IDX-1197 in patients with HRR mutation.
There are two parts to this study: Phase 1b, IDX-1197 dose-selection study to determine RP2D and Phase 2a, non-randomized parallel dose expansion study to confirm RP2D.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 19 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically confirmed cancers that have HRR mutation and are failed to standard therapy or for which standard or curative therapy does not exist or is not considered appropriate by the Investigator.
- •Measurable disease according to RECIST, v1.
- •Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-2
- •Must have recovered from all side effects of their most recent systemic or local treatment (<CTCAE grade 3)
- •Life expectancy greater than 12weeks
排除标准
- •Prior treatment with PARP inhibitors
- •Symptomatic CNS metastases
- •History of or known carcinomatous meningitis
- •Concurrent administration of any anti-cancer therapies other than those administered in this study
- •Pregnant or lactating women
- •Refractory nausea and vomiting, malabsorption, total gastrectomy, external biliary shunt or significant bowel resection that would preclude adequate absorption.
- •Uncontrolled medical illness (such as infection requiring treatment with intravenous antibiotics)
- •Severe or unstable angina, myocardial infarction or ischemia requiring coronary artery bypass graft or stent within the previous 6 months, symptomatic congestive heart failure, arterial or venous thromboembolic events (e.g., pulmonary embolism, cerebrovascular accident including transient ischemic attacks), or clinically significant ventricular arrhythmias within 6 months prior to enrollment or New York Heart Association (NYHA) Class II to IV heart disease.
- •Immunocompromised patients, e.g., patients who are known to be serologically positive for human immunodeficiency virus (HIV)
- •Known hypersensitivity to IDX-1197 or any of the excipients of the product
研究组 & 干预措施
IDX-1197
Experimental
Patient will be receive IDX-1197HCl once daily for 28 continuous days
干预措施: IDX-1197 (Drug)
结局指标
主要结局
objective response rate (ORR)
时间窗: Up to 24 weeks
Confirmed objective response rate (ORR) determined by the Investigator using Response Evaluation Criteria In Solid Tumors, Version 1.1 (RECIST, v1.1).
次要结局
未报告次要终点
研究者
研究点 (26)
Loading locations...
相似试验
进行中（未招募）
1 期
Study to Assess the Safety, Tolerability, and Efficacy of IDX-1197 in Combination With XELOX or Irinotecan in Patients With Advanced Gastric CancerGastric CancerNCT04725994Idience Co., Ltd.87
已完成
1 期
A Phase 1 Study of Nivolumab (BMS-936558) in Subjects With Advanced or Recurrent MalignanciesMetastatic Castration-resistant Prostrate CancerMetastatic MelanomaRenal Cell CarcinomaNon-small Cell Lung CancerNCT00730639Bristol-Myers Squibb395
已完成
1 期
Trial of PXD101 (Belinostat) in Combination With Idarubicin to Treat AML Not Suitable for Standard Intensive TherapyAcute Myeloid LeukemiaNCT00878722Valerio Therapeutics41
终止
1 期
Study of Intravenous RXDX-107 in Patients With Solid TumorsSolid TumorNCT02548390Hoffmann-La Roche70
已完成
1 期
A Phase I/II Clinical Trial of PXD101 in Combination With Doxorubicin in Patients With Soft Tissue SarcomasDose Escalation: Solid TumorsMTD: Soft Tissue SarcomasNCT00878800Valerio Therapeutics41